Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancer
Active Project Grant Awarded Last action
- Award ID
- R01CA276826
- Recipient
-
University Of Southern California UEI G88KLJR3KYT5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,494,218
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 63% complete
- Place of performance
- Los Angeles, CA 90033, USA
Award details come from USAspending.gov.
Description
- Abstract
- There is strong evidence that prostate cancer (PCA) is a heritable phenotype. In addition to greater risk observed in men with a family history of PCA, genome-wide association studies (GWAS) have identified over 400 common independent risk variants, which explain ~40% of the familial risk. IT is increasingly recognized that much of the unknown heritability for PCA may also be due to variants of low minor allele frequency (500,000 controls within biobanks and cohorts in the US and UK and conduct exome-wide analyses of overall PCA and aggressive disease phenotypes. In aim 2, we will examine the combined effect of rare coding variants and a polygenic risk score (PRS) on risk of overall PCA and aggressive disease and estimate absolute risks for the combined effects of rare coding variants and PRS in prospective biobanks and cohorts across populations. In aim 3, we will integrate somatic tumor and germline variation data to inform genes and biological pathways involved in PCA and aggressive disease. For this aim, we have assembled a somatic resource of >7,000 PCA patients with germline exome/PRS data and somatic mutation profiling from WES and WGS studies, including >2,000 with transcriptomic data. We expect this study to provide the most comprehensive and well-powered examination of rare coding variation in PCA across populations to date. Findings from this study will have immediate clinical translation by informing personalized risk prediction and the development of novel risk-based screening strategies for overall and aggressive PCA. Integrating germline and somatic data will also define biological mechanisms that may be clinically important for understanding how to treat and prevent PCA and lethal disease across populations.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $660,688 | |
| Amendment | $666,878 | |
| Amendment | $634,844 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $765,904 | |
| Original award | $765,904 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Geisinger Clinic | $89,000 | |
| Institute Of Cancer Research: Royal Cancer Hospital (The) | $30,000 | |
| Brigham & Womens Hospital Inc. | $183,577 | |
| University Of California, LOS Angeles | $90,000 | |
| Institute Of Cancer Research: Royal Cancer Hospital (The) | $37,155 | |
| The Regents Of The University Of Colorado | $247,659 | |
| University Of California, LOS Angeles | $185,540 | |
| Geisinger Clinic | $93,837 | |
| Fred Hutchinson Cancer Center | $270,646 |
Quick answers
Who received award R01CA276826?
R01CA276826 was awarded to University Of Southern California by National Cancer Institute (National Institutes of Health) on September 20, 2023.
How much is award R01CA276826 worth?
$3,494,218 has been obligated on R01CA276826.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award